Sign In
Buy DARE
$2.05
-0.0900 (-4.21%)
At Close: Jun 03, 2026
Developed and evaluated specifically for women, DARE to PLAY™ Sildenafil Cream is a first-of-its-kind female arousal cream, a non-hormonal topical cream shown in clinical studies to increase genital
Daré Bioscience, Inc. ( DARE ) Discusses DARE to PLAY Sildenafil Cream as a Treatment Option for Female Genital Arousal Concerns November 17, 2025 12:00 PM EST Company Participants Jennifer Kiang Sab
Dare Bioscience (NASDAQ:DARE) Stock Passes Below 200-Day Moving Average – What’s Next?
03:44am, Saturday, 22'nd Nov 2025
Shares of Dare Bioscience, Inc. (NASDAQ: DARE - Get Free Report) crossed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $2.36 and traded as low as
Daré Bioscience, Inc. (DARE) Q3 2025 Earnings Call Transcript
07:41pm, Thursday, 13'th Nov 2025
Daré Bioscience, Inc. ( DARE ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants MarDee Haring-Layton - Chief Accounting Officer Sabrina Johnson - CEO, President, Principal Fin
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates
06:11pm, Thursday, 13'th Nov 2025
Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.55 per share a year ago.
Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update
04:01pm, Thursday, 13'th Nov 2025
DARE to PLAY™ Sildenafil Cream on Track to Launch Before Year End via 503B Pathway, Paving the Way for Near-Term Product Revenue Positive Interim DSMB Outcome for Ovaprene® Phase 3 Study Supports C
Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025
08:00am, Thursday, 06'th Nov 2025
SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising sci
Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research
08:00am, Wednesday, 24'th Sep 2025
Engagement Will Expand Daré's Engagement in Advancing Women's Health Innovation and Provide Insights into One of the Most Significant Unmet Needs in Maternal Care Engagement Will Expand Daré's Engag
Daré Bioscience, Inc. (DARE) Q2 2025 Earnings Call Transcript
07:48pm, Thursday, 14'th Aug 2025
Daré Bioscience, Inc. (NASDAQ:DARE ) Q2 2025 Earnings Conference Call August 14, 2025 4:30 PM ET Company Participants MarDee J. Haring-Layton - Chief Accounting Officer Sabrina Martucci Johnson - CEO
Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates
06:15pm, Thursday, 14'th Aug 2025
Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to earnings of $1.52 per share a year ago.
Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update
04:01pm, Thursday, 14'th Aug 2025
DARE to PLAY™ Sildenafil Cream on Track for Q4 2025 Launch via 503B Compounding Pathway; Positioned for Product Revenue Beginning in Q4 2025
Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025
08:00am, Thursday, 07'th Aug 2025
SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company with a sole focus of closing the gap in women's health between promising science and
Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream
08:00am, Tuesday, 29'th Jul 2025
A first-of-its-kind solution for women's arousal in a proprietary topical formulation demonstrated to work where women need it most
UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar
01:47pm, Monday, 21'st Jul 2025
A first-of-its-kind solution for women's arousal - the same active ingredient as in Viagra® for men - in a proprietary topical formulation demonstrated to work where women need it most
Crude Oil Moves Lower; Daré Bioscience Shares Jump
01:09pm, Monday, 14'th Jul 2025
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 0.4% on Monday.
